Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
866 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | recruiting | Phase 3 | 550 | Shanghai Henlius BiotechINDUSTRY | 17 | Feb 27, 2026 | clinicaltrials |
| NCT06905197 | A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1) | recruiting | Phase 1 | 140 | Dizal PharmaceuticalsINDUSTRY | 2 | Feb 27, 2026 |
| clinicaltrials |
| NCT02790983 | Primary Tumor Research and Outcomes Network(PTRON) | recruiting | — | 1,350 | AO Innovation Translation CenterOTHER | 9 | Feb 25, 2026 | clinicaltrials |
| NCT05549297 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | recruiting | Phase 3 | 540 | Immunocore LtdINDUSTRY | 12 | Feb 25, 2026 | clinicaltrials |
| NCT06112314 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)(PRISM-MEL-301) | recruiting | Phase 3 | 680 | Immunocore LtdINDUSTRY | 26 | Feb 25, 2026 | clinicaltrials |
| NCT06521554 | A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | recruiting | Phase 1 | 200 | Nuvalent Inc.INDUSTRY | 3 | Feb 25, 2026 | clinicaltrials |
| NCT07156136 | Study of IMC-P115C in Advanced PRAME-Positive Cancers | recruiting | Phase 1 | 140 | Immunocore LtdINDUSTRY | 4 | Feb 25, 2026 | clinicaltrials |
| NCT04676828 | Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer(ASPECT) | recruiting | N/A | 90 | University of AarhusOTHER | 2 | Feb 24, 2026 | clinicaltrials |
| NCT06267729 | Study of AZD0754 in Participants With Metastatic Prostate Cancer(APOLLO) | recruiting | Phase 1 / Phase 2 | 60 | AstraZenecaINDUSTRY | 3 | Feb 23, 2026 | clinicaltrials |
| NCT05720130 | Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). | recruiting | Phase 1 / Phase 2 | 100 | AdvanCell Pty LimitedINDUSTRY | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05991388 | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma(Glo-BNHL) | recruiting | Phase 2 / Phase 3 | 210 | University of BirminghamOTHER | 7 | Feb 20, 2026 | clinicaltrials |
| NCT06264167 | NODE (groiN ultrasOunD cancEr)(NODE) | recruiting | N/A | 30 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06450106 | Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy | recruiting | Phase 1 | 18 | SURGE TherapeuticsINDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT06999980 | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)(Neo IRENIE) | recruiting | Phase 2 | 494 | Melanoma Institute AustraliaOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07421739 | Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects | recruiting | — | 15 | Aura BiosciencesINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06151236 | Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma | recruiting | Phase 2 | 20 | Melanoma Institute AustraliaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06830759 | Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma(EpcoReal) | recruiting | — | 700 | AbbVieINDUSTRY | 13 | Feb 17, 2026 | clinicaltrials |
| NCT06973863 | A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 40 | PharmaEngineINDUSTRY | 2 | Feb 13, 2026 | clinicaltrials |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | recruiting | Phase 3 | 550 | Jazz PharmaceuticalsINDUSTRY | 15 | Feb 10, 2026 | clinicaltrials |
| NCT06634849 | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). | recruiting | Phase 1 / Phase 2 | 30 | Pathios Therapeutics Pty LtdINDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04895436 | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)(ReVenG) | recruiting | Phase 2 | 75 | AbbVieINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT03073278 | Focal Radiotherapy for Previously Treated Prostate Cancer Patients | recruiting | N/A | 36 | Royal North Shore HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06127407 | Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen(CHONQUER) | recruiting | Phase 3 | 136 | Servier Bio-Innovation LLCINDUSTRY | 17 | Feb 6, 2026 | clinicaltrials |
| NCT06432478 | 3D Printed Custom Applicators for HDR BT (DISCO) | recruiting | N/A | 10 | Royal North Shore HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06547398 | Prostate Adaptive Radiation Therapy | recruiting | N/A | 130 | Royal North Shore HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06650033 | Pelvis Adaptive Radiotherapy (ART)(Pelvis ART) | recruiting | N/A | 280 | Royal North Shore HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07387978 | A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation Treatment(PBM) | recruiting | N/A | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT03340129 | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)(ABC-X) | recruiting | Phase 2 | 218 | Melanoma Institute AustraliaOTHER | 2 | Feb 2, 2026 | clinicaltrials |
| NCT05180097 | Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | recruiting | Phase 2 | 84 | Canadian Cancer Trials GroupNETWORK | 2 | Feb 2, 2026 | clinicaltrials |
| NCT06926920 | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 100 | Gilead SciencesINDUSTRY | 3 | Jan 30, 2026 | clinicaltrials |
| NCT06644300 | Study of BM230 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 123 | Suzhou Biomissile Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 29, 2026 | clinicaltrials |
| NCT06208657 | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | recruiting | Phase 1 / Phase 2 | 90 | Australian & New Zealand Children's Haematology/Oncology GroupOTHER | 2 | Jan 28, 2026 | clinicaltrials |
| NCT06840119 | Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | recruiting | Phase 1 / Phase 2 | 600 | Immunocore LtdINDUSTRY | 6 | Jan 28, 2026 | clinicaltrials |
| NCT06923761 | EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)(EMITT-1) | recruiting | Phase 1 / Phase 2 | 300 | Grey Wolf TherapeuticsOTHER | 4 | Jan 28, 2026 | clinicaltrials |
| NCT07016490 | A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 15 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07138222 | IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma(IMPACT) | recruiting | — | 80 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06921837 | A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer | recruiting | Phase 1 / Phase 2 | 122 | Bolt Biotherapeutics, Inc.INDUSTRY | 3 | Jan 27, 2026 | clinicaltrials |
| NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | recruiting | Phase 1 | 27 | SAPU NANO (US) LLCINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07112222 | A Study of LM-350 in Subjects With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 80 | LaNova Medicines LimitedINDUSTRY | 2 | Jan 26, 2026 | clinicaltrials |
| NCT07363057 | A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors(GIANTS-1) | recruiting | Phase 2 | 15 | GI Innovation, Inc.INDUSTRY | 1 | Jan 26, 2026 | clinicaltrials |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 892 | GlaxoSmithKlineINDUSTRY | 28 | Jan 23, 2026 | clinicaltrials |
| NCT06302426 | Trial of INI-4001 in Patients With Advanced Solid Tumours | recruiting | Phase 1 | 50 | Inimmune CorporationINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06445738 | Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)(PROSPECTIVE) | recruiting | N/A | 1,400 | Breast Cancer Trials, Australia and New ZealandOTHER | 2 | Jan 15, 2026 | clinicaltrials |
| NCT06830850 | A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 25 | Atridia Pty Ltd.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06234423 | A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 263 | OnCusp Therapeutics, Inc.INDUSTRY | 2 | Jan 14, 2026 | clinicaltrials |
| NCT05759728 | A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 45 | Carina Biotech LimitedINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06163430 | A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)(CARDINAL) | recruiting | Phase 1 / Phase 2 | 180 | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 9 | Jan 12, 2026 | clinicaltrials |
| NCT06887348 | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3(RPx) | recruiting | — | 50 | Replimune, Inc.INDUSTRY | 2 | Jan 12, 2026 | clinicaltrials |
| NCT07334301 | A Multi-Arm, Platform Trial For Relapsed Neuroblastoma(BEACON2) | recruiting | Phase 1 / Phase 2 | 160 | University of BirminghamOTHER | 5 | Jan 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials